Effect of Chromium Weight Reduction on Adult Asthma Control (ECWAC)
This phase IV randomized controlled trial is designed to evaluate the effects of chromium picolinate supplementation in obese adults with stable asthma. A total of 60 participants will be recruited from Ain Shams University Hospitals and randomly assigned to receive either 400 mcg of chromium picolinate daily or a matching placebo for 12 weeks, in addition to standard asthma therapy.
The study aims to explore the interaction between metabolic dysfunction and asthma, as obesity-related asthma is often associated with systemic inflammation, insulin resistance, and dyslipidemia. These factors may contribute to poorer asthma control and impaired pulmonary function, and therefore represent potential targets for adjunctive therapeutic interventions such as chromium supplementation.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Study Design and Setting This study is a phase IV randomized controlled clinical trial (RCT) involving 60 adult patients diagnosed with asthma. Participants will be recruited from the outpatient clinic and pulmonary function unit of the Chest Department at Ain Shams University Hospitals.
Study Type: Phase IV randomized controlled clinical trial (RCT) Study Setting: Outpatient clinic and pulmonary function unit, Chest Department, Ain Shams University Hospitals Study Population: Adult patients with asthma, obesity, and diabetes mellitus
Sampling and Randomization Participants will be randomly assigned to study groups using computer-generated randomization sequences. Allocation concealment will be ensured through the use of sealed, opaque envelopes.
Ethical Considerations
The study protocol will be explained clearly to all eligible participants prior to enrollment.
The study will commence only after obtaining approval from the Ethical Committee of the Faculty of Medicine, Ain Shams University.
Written informed consent will be obtained from all participants prior to inclusion.
Participant safety will be prioritized, and all efforts will be made to minimize potential risks.
Confidentiality and anonymity of participant data will be strictly maintained. All participants will have an equal chance of being assigned to either study group.
No deceptive practices will be used during the study. Participants will have the right to withdraw from the study at any time without any consequences.
Study Procedures
All eligible participants will undergo the following assessments:
Demographic Data Collection: Age, sex, smoking status, and body mass index (BMI) Clinical Assessment: Detailed medical history including environmental exposures, potential risk factors, comorbidities, and duration of disease
Concomitant Care All participants will continue receiving standard asthma therapy throughout the study period.
Participants will be instructed to maintain a consistent intake of chromium-rich foods during the study to avoid dietary confounding.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Hieba Gamal Gamal Ezz El Regal, PhD
- Numéro de téléphone: +2 01002041611
- E-mail: hiebagamal24@med.asu.edu.eg
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age: 18-65 years
- Confirmed asthma diagnosis according to GINA criteria (7)
- Asthma stable for at least 4 weeks (no acute exacerbation)
- BMI of 30 kg/m² (obese category)
- Stable inhaled corticosteroid + LABA regimen in the last 4 weeks
- The patient is compliant on his asthma medication
- Willing and able to provide informed consent
- willing to continue in the study, follow investigator instructions
Exclusion Criteria:
- - Recent asthma exacerbation (within the last 4 weeks)
- Any change in asthma medications within 4 weeks
- renal or hepatic disease
- Use of lipid-lowering drugs or supplements in the past 3 months
- Use of Vitamin C, prostaglandin inhibitors, such as aspirin, oxalate, and antacids
- Current pregnancy or lactation
- Known allergy to chromium or adverse reaction to supplementation
- Participation in another interventional study in the past month
- History of heavy metal toxicity or chromium sensitivity
- Being on any weight control diet
- Being on a supplement containing chromium
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Standard of Care
All participants continue standard asthma therapy and management - Study participants will be instructed to keep their dietary consumption of chromium rich foods constant all over the study period. |
|
|
Expérimental: Chromium Picolinate
Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium. Taken once daily for 12 weeks. |
Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium. Taken once daily for 12 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in asthma control
Délai: from baseline to 12 weeks
|
Change in Asthma Control Test (ACT) Score (points; range 5-25)
|
from baseline to 12 weeks
|
|
Spirometry
Délai: from baseline to 12 weeks
|
Forced Expiratory Volume in 1 second (FEV₁) - L or % predicted
|
from baseline to 12 weeks
|
|
Frequency of rescue medication use
Délai: from baseline to 12 weeks
|
Frequency of Asthma Inhalers used
|
from baseline to 12 weeks
|
|
Asthma exacerbation frequency
Délai: from baseline to 12 weeks
|
Asthma exacerbation frequency
|
from baseline to 12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Lipid Profile
Délai: From baseline to 12 weeks
|
Change in fasting total, HDL, LDL Cholesterol in addition to the triglycerides
|
From baseline to 12 weeks
|
|
Anthropometric Measurements
Délai: From baseline to 12 weeks
|
Change in Body Mass Index (BMI) Unit of Measure: kg/m²
|
From baseline to 12 weeks
|
|
Incidence of Treatment-Emergent Adverse Events
Délai: Monthly from baseline to 3 months
|
The outcome measure will assess the frequency of adverse effects occurring during the study period.
|
Monthly from baseline to 3 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Poids
- Maladies du système immunitaire
- Maladies des voies respiratoires
- Changements de poids corporel
- Maladies pulmonaires
- Maladies bronchiques
- Maladies pulmonaires obstructives
- Hypersensibilité respiratoire
- Hypersensibilité immédiate
- Hypersensibilité
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Perte de poids
- Asthme
- acide picolinique
Autres numéros d'identification d'étude
- FMASU R62/2026 (Identificateur de registre: Ain Shams Faculty of Medicine Institutional Review Board)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .